A proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051297

Enrollment

Unknown

Registered

2021-09-18

Start date

2021-09-03

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Vaccine and Psychosis

Interventions

experimental group:Covid-19 Vaccine injection

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with depression, schizophrenia, bipolar disorder.

Exclusion criteria

Exclusion criteria: Patients with severe allergic constitution, patients with serious physical disease, neurological disease.

Design outcomes

Primary

Measure	Time frame
Adverse events;anti-body of Covid-19 virus;	—

Countries

China

Contacts

Public ContactZhuo Chuanjun

Nankai Unievesitry Affiliated Tianjin Fourth Center Hospital

chuanjunzhuotjmh@vip.163.com+86 22 24394542

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026